Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) provides standardised criteria for evaluating changes in tumour burden in solid-tumour clinica...

Despite the rise of decentralised trial models, clinical research delivery remains fundamentally dependent on sites. Yet the current U.S. site network is overburdene...

Precision medicine has transformed the landscape of cancer treatment by shifting from histology-based to biomarker-driven therapies and enabling targeted interventio...

Elevating Patient Care Around the world, individual physicians and healthcare providers strive to bring the highest standard of affordable care to their patient p...

The biggest risks to a global study occur long before the first patient is enrolled. The illusory ideal for every sponsor running a global study is to manage one ...